ResearcherSeoul National UniversityActive in the last 2 years
Bo‐Mi Kim
Matched on ORCID iD 0000-0003-2306-0738; OpenAlex author ID A5100413723. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 7
2023: 1 paper · 2024: none · 2025: 2 papers
Papers 3
- Distinct microbiome composition and reduced interactions in patients with pancreatic cancer. Co-author DOI 10.3389/fmicb.2025.1555479↗
- Identification of patients with advanced pancreatic cancer who might benefit from third-line chemotherapy. Co-author DOI 10.4251/wjgo.v17.i2.100167↗
- Real-world dose reduction of standard and modified FOLFIRINOX in metastatic pancreatic cancer: a systematic review, evidence-mapping, and meta-analysis. Co-author DOI 10.1177/17588359231175441↗
Closest collaborators
The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Jinwoo Ahn · 3 shared papers, 2023–2025 · strength 0.68
- Paper Identification of patients with advanced pancreatic cancer who might benefit from third-line chemotherapy. DOI 10.4251/wjgo.v17.i2.100167↗
- Paper Distinct microbiome composition and reduced interactions in patients with pancreatic cancer. DOI 10.3389/fmicb.2025.1555479↗
- Paper Real-world dose reduction of standard and modified FOLFIRINOX in metastatic pancreatic cancer: a systematic review, evi… DOI 10.1177/17588359231175441↗
- Jong-Chan Lee · 3 shared papers, 2023–2025 · strength 0.68
- Paper Identification of patients with advanced pancreatic cancer who might benefit from third-line chemotherapy. DOI 10.4251/wjgo.v17.i2.100167↗
- Paper Distinct microbiome composition and reduced interactions in patients with pancreatic cancer. DOI 10.3389/fmicb.2025.1555479↗
- Paper Real-world dose reduction of standard and modified FOLFIRINOX in metastatic pancreatic cancer: a systematic review, evi… DOI 10.1177/17588359231175441↗
- Kwangrok Jung · 3 shared papers, 2023–2025 · strength 0.68
- Paper Identification of patients with advanced pancreatic cancer who might benefit from third-line chemotherapy. DOI 10.4251/wjgo.v17.i2.100167↗
- Paper Distinct microbiome composition and reduced interactions in patients with pancreatic cancer. DOI 10.3389/fmicb.2025.1555479↗
- Paper Real-world dose reduction of standard and modified FOLFIRINOX in metastatic pancreatic cancer: a systematic review, evi… DOI 10.1177/17588359231175441↗
- Jin‐Hyeok Hwang · 3 shared papers, 2023–2025 · strength 0.68
- Paper Identification of patients with advanced pancreatic cancer who might benefit from third-line chemotherapy. DOI 10.4251/wjgo.v17.i2.100167↗
- Paper Distinct microbiome composition and reduced interactions in patients with pancreatic cancer. DOI 10.3389/fmicb.2025.1555479↗
- Paper Real-world dose reduction of standard and modified FOLFIRINOX in metastatic pancreatic cancer: a systematic review, evi… DOI 10.1177/17588359231175441↗
- Jaihwan Kim · 3 shared papers, 2023–2025 · strength 0.68
- Paper Identification of patients with advanced pancreatic cancer who might benefit from third-line chemotherapy. DOI 10.4251/wjgo.v17.i2.100167↗
- Paper Distinct microbiome composition and reduced interactions in patients with pancreatic cancer. DOI 10.3389/fmicb.2025.1555479↗
- Paper Real-world dose reduction of standard and modified FOLFIRINOX in metastatic pancreatic cancer: a systematic review, evi… DOI 10.1177/17588359231175441↗
- Kyoung Un Park · 1 shared paper, 2025 · strength 0.23
- Jae Hyup Jung · 1 shared paper, 2023 · strength 0.17
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.